News from CSL Behring Canada A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 14, 2017, 09:30 ET FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's...


Jan 09, 2017, 09:55 ET AFSTYLA®, for Haemophilia A, Receives European Commission Approval

Global biotherapeutics leader CSL Behring announced today that the European Commission has granted marketing authorisation for AFSTYLA®...


Dec 22, 2016, 10:00 ET CSL CEO Says Holistic Approach to Business is Essential to Corporate Sustainability, the Company's Value Chain and Patients

CSL Limited (ASX: CSL), parent company of CSL Behring, has recorded another strong performance in corporate responsibility, outlining in its...


Dec 14, 2016, 13:58 ET Health Canada Approves CSL Behring's AFSTYLA™ for the Treatment of Hemophilia A

-AFSTYLA is the first and only single-chain recombinant factor VIII for hemophilia A, specifically designed for long-lasting protection from bleeds...


Dec 03, 2016, 20:30 ET CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting

Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION®...


Dec 02, 2016, 09:51 ET The Lancet Respiratory Medicine Publishes RAPID Extension Study Data on Effect of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD)

Global biotherapeutics leader CSL Behring announced today that The Lancet Respiratory Medicine, a specialty journal, published findings of the...


Nov 15, 2016, 13:25 ET CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial

CSL Behring today announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel...


Nov 14, 2016, 10:00 ET AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use...


Oct 27, 2016, 14:30 ET CSL Behring Receives 2016 Marcum Innovator Breakthrough Award for Pioneering New Advancements in the Biotech/Healthcare Field

Marcum LLP and Philadelphia SmartCEO magazine have recognized CSL Behring with the 2016 Innovator Breakthrough Award for developing novel products...


Oct 07, 2016, 15:00 ET Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma

- More than 1,000 plasma donations may be needed to treat one adult patient with a rare disease for a year - During International...


Sep 29, 2016, 09:46 ET Japan's Ministry of Health, Labour and Welfare (MHLW) Approves CSL Behring's IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals

Global biotherapeutics leader CSL Behring announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved...


Aug 30, 2016, 09:00 ET FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's Biologics License Application...


Jul 27, 2016, 10:00 ET CSL Behring Presents Pivotal Efficacy Data for AFSTYLA® In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress

 CSL Behring today presented data from a Phase III pivotal study of AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain]...


Jul 26, 2016, 10:00 ET CSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at the World Federation of Hemophilia 2016 World Congress

CSL Behring today announced new data from its Phase III PROLONG-9FP clinical development program evaluating IDELVION® [Coagulation Factor IX...


Jul 25, 2016, 11:00 ET CSL Behring Awards Emerging Coagulation Specialists Across the Globe to Support Advancements in the Care of Patients with Bleeding Disorders

 CSL Behring today announced that the company has named five recipients of the 2016 CSL Behring Professor Heimburger Award for...


Jul 19, 2016, 10:00 ET CSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress

 CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the XXXII...


Jul 18, 2016, 11:55 ET U.S. FDA Approves CSL Behring's Berinert® as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE)

 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert [C1 Esterase Inhibitor (Human)],...


Jun 23, 2016, 05:30 ET CSL Behring Announces Immunoglobulin Research Grant Winners

 CSL Behring announced today at the Peripheral Nerve Society's Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow,...


Jun 20, 2016, 09:00 ET AFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A - Now Available in the U.S.

 Driven by its promise to save lives, CSL Behring announced today that AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain],...


May 11, 2016, 13:30 ET IDELVION® -- CSL Behring's Innovative Therapy for Hemophilia B Patients -- Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug Administration

 CSL Behring announced today it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration (FDA) for...


May 11, 2016, 11:00 ET European Commission Approves IDELVION® --CSL Behring's Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals

 CSL Behring announced today that the European Commission has approved IDELVION® [albutrepenonacog alfa], its innovative, long-acting...


Apr 25, 2016, 09:00 ET CSL Behring Commemorates 100 Years of Delivering on its Promise to Develop Innovative Therapies for People with Life-threatening Medical Conditions

 CSL Behring today commemorated 100 years of developing and delivering innovative therapies to treat people with life-threatening medical...


Mar 21, 2016, 09:18 ET IDELVION® for Hemophilia B Now Available in the U.S.

 CSL Behring announced today that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting...


Mar 15, 2016, 09:30 ET CSL Behring sponsors IDF webinar series for young adults living with primary immunodeficiencies

In honor of the upcoming World Primary Immunodeficiencies (PI) Week, CSL Behring is proud to sponsor Immune Deficiency Foundation's new PI Voices,...


Mar 09, 2016, 09:00 ET CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy Objectives

Patients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them...